Plus Therapeutics, Inc. today announced it will present data from two ongoing clinical trials evaluating the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome ( 186 RNL), in recurrent glioblastoma and leptomeningeal metastases at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM), being held October 15-19, 2022 in Barcelona, Spain.
October 4, 2022
· 5 min read